Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity

US6686397B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Gerhard Jaehne · Frankfurt, DE
• Volker Krone · Flörsheim, DE
• Martin Bickel · Frankfurt am Main, DE
• Matthias Gossel · Frankfurt am Main, DE

Key dates

• Filing date: Aug 29, 2002
• Grant date: Feb 3, 2004
• Expiry date: Aug 29, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed: Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.